APEIRON Biologics AG-Product Pipeline Review-2015

APEIRON Biologics AG-Product Pipeline Review-2015

  • Products Id :- GMDHC06924CDB
  • |
  • Pages: 37
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

APEIRON Biologics AG-Product Pipeline Review-2015


Global Markets Direct's, 'APEIRON Biologics AG-Product Pipeline Review-2015', provides an overview of the APEIRON Biologics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of APEIRON Biologics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of APEIRON Biologics AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of APEIRON Biologics AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the APEIRON Biologics AG's pipeline products

Reasons To Buy

Evaluate APEIRON Biologics AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of APEIRON Biologics AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the APEIRON Biologics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of APEIRON Biologics AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of APEIRON Biologics AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of APEIRON Biologics AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

APEIRON Biologics AG Snapshot 5

APEIRON Biologics AG Overview 5

Key Information 5

Key Facts 5

APEIRON Biologics AG-Research and Development Overview 6

Key Therapeutic Areas 6

APEIRON Biologics AG-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

APEIRON Biologics AG-Pipeline Products Glance 12

APEIRON Biologics AG-Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

APEIRON Biologics AG-Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

APEIRON Biologics AG-Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

APEIRON Biologics AG-Unknown Stage Pipeline Products 17

Unknown Products/Combination Treatment Modalities 17

APEIRON Biologics AG-Drug Profiles 18

APN-201 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

APN-311 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

APN-301 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

APN-401 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

APN-411 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Drugs for Cancer and Related Conditions 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

APEIRON Biologics AG-Pipeline Analysis 28

APEIRON Biologics AG-Pipeline Products by Target 28

APEIRON Biologics AG-Pipeline Products by Route of Administration 29

APEIRON Biologics AG-Pipeline Products by Molecule Type 30

APEIRON Biologics AG-Pipeline Products by Mechanism of Action 31

APEIRON Biologics AG-Recent Pipeline Updates 32

APEIRON Biologics AG-Dormant Projects 34

APEIRON Biologics AG-Locations And Subsidiaries 35

Head Office 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

APEIRON Biologics AG, Key Information 5

APEIRON Biologics AG, Key Facts 5

APEIRON Biologics AG-Pipeline by Indication, 2015 7

APEIRON Biologics AG-Pipeline by Stage of Development, 2015 8

APEIRON Biologics AG-Monotherapy Products in Pipeline, 2015 9

APEIRON Biologics AG-Out-Licensed Products in Pipeline, 2015 10

APEIRON Biologics AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 11

APEIRON Biologics AG-Phase III, 2015 12

APEIRON Biologics AG-Phase II, 2015 13

APEIRON Biologics AG-Phase I, 2015 14

APEIRON Biologics AG-Preclinical, 2015 15

APEIRON Biologics AG-Discovery, 2015 16

APEIRON Biologics AG-Unknown, 2015 17

APEIRON Biologics AG-Pipeline by Target, 2015 28

APEIRON Biologics AG-Pipeline by Route of Administration, 2015 29

APEIRON Biologics AG-Pipeline by Molecule Type, 2015 30

APEIRON Biologics AG-Pipeline Products by Mechanism of Action, 2015 31

APEIRON Biologics AG-Recent Pipeline Updates, 2015 32

APEIRON Biologics AG-Dormant Developmental Projects,2015 34

List of Figures

APEIRON Biologics AG-Pipeline by Top 10 Indication, 2015 7

APEIRON Biologics AG-Pipeline by Stage of Development, 2015 8

APEIRON Biologics AG-Monotherapy Products in Pipeline, 2015 9

APEIRON Biologics AG-Pipeline by Top 10 Target, 2015 28

APEIRON Biologics AG-Pipeline by Top 10 Route of Administration, 2015 29

APEIRON Biologics AG-Pipeline by Top 10 Molecule Type, 2015 30

APEIRON Biologics AG-Pipeline Products by Top 10 Mechanism of Action, 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com

Current R&D Portfolio of APEIRON Biologics AG; APEIRON Biologics AG - Key Therapeutics; APEIRON Biologics AG - Pipeline Overview and Promising Molecules; APEIRON Biologics AG - News; APEIRON Biologics AG - Latest Updates; APEIRON Biologics AG - Pipeline; APEIRON Biologics AG - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97500
Site License
USD 3000 INR 195000
Corporate User License
USD 4500 INR 292500



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@] kenresearch.com